Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis

Abstract

Autologous hematopoietic stem cell transplantation (HSCT) utilizing a myeloablative regimen containing total body irradiation has been performed in patients with systemic sclerosis (SSc), but with substantial toxicity. We, therefore, conducted a phase I non-myeloablative autologous HSCT study in 10 patients with SSc and poor prognostic features. PBSC were mobilized with CY and G-CSF. The PBSC graft was cryopreserved without manipulation and re-infused after the patient was treated with a non-myeloablative conditioning regimen of 200 mg/kg CY and 7.5 mg/kg rabbit antithymocyte globulin. There was a statistically significant improvement of modified Rodnan skin score whereas cardiac (ejection fraction, pulmonary arterial pressure), pulmonary function (DLCO) and renal function (creatinine) remained stable without significant change. One patient with advanced disease died 2 years after the transplant from progressive disease. After median follow-up of 25.5 months, the overall and progression-free survival rates are 90 and 70% respectively. Autologous HSCT utilizing a non-myeloablative conditioning regimen appears to result in improved skin flexibility similar to a myeloablative TBI containing regimen, but without the toxicity and risks associated with TBI.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Adams KM, Nelson JL . Microchimerism: an investigative frontier in autoimmunity and transplantation. JAMA 2004; 291: 1127–1131.

    Article  CAS  PubMed  Google Scholar 

  2. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y . Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603–610.

    Article  CAS  PubMed  Google Scholar 

  3. Abraham DJ, Varga J . Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587–595.

    Article  CAS  PubMed  Google Scholar 

  4. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577–584.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726–739.

    Article  PubMed  Google Scholar 

  6. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602–1610.

    CAS  PubMed  Google Scholar 

  7. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR registry. Ann Rheum Dis 2004; 63: 974–981.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. McSweeney P, Furst D, Crofford L, McDonagh K, Sullivan K . High-dose immunosuppressive therapy (HDIT) for severe systemic sclerosis (SSc): long-term survivors show continued improvement of function and skin with stability in the lungs. Blood 2004; 104: 46a.

    Google Scholar 

  9. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007 (E-pub ahead of print).

  10. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006; 54: 3750–3760.

    Article  PubMed  Google Scholar 

  11. Statkute L, Verda L, Oyama Y, Traynor A, Villa M, Shook T et al. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 317–329.

    Article  CAS  PubMed  Google Scholar 

  12. Burt RK, Patel D, Thomas J, Yeager A, Traynor A, Heipe F et al. The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis. Bone Marrow Transplant 2004; 34: 745–751.

    Article  CAS  PubMed  Google Scholar 

  13. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527–535.

    Article  CAS  PubMed  Google Scholar 

  14. Voltarelli JC, Couri CEB, Oliveira MC, Moraes DA, Pieroni F, Countinho M et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes. JAMA 2007; 297: 1568–1576.

    Article  CAS  PubMed  Google Scholar 

  15. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892–1896.

    CAS  PubMed  Google Scholar 

  16. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma lung study research group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.

    Article  CAS  PubMed  Google Scholar 

  17. Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK . Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant 2002; 29: 81–85.

    Article  CAS  PubMed  Google Scholar 

  18. Marie I, Levesque H, Ducrotte P, Denis P, Hellot MF, Benichou J et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001; 96: 77–83.

    Article  CAS  PubMed  Google Scholar 

  19. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983–2989.

    Article  CAS  PubMed  Google Scholar 

  20. Furst DE, Clements PJ, Hillis S, Lachenbruch PA, Miller BL, Sterz MG et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989; 32: 584–593.

    Article  CAS  PubMed  Google Scholar 

  21. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB . Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364–372.

    Article  CAS  PubMed  Google Scholar 

  22. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351–1358.

    Article  CAS  PubMed  Google Scholar 

  23. Nadashkevich O, Davis P, Fritzler M, Kovalenko W . A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205–212.

    Article  CAS  PubMed  Google Scholar 

  24. Casas JA, Saway PA, Villarreal I, Nolte C, Menajovsky BL, Escudero EE et al. 5-fluorouracil in the treatment of scleroderma: a randomized, double blind, placebo controlled international collaborative study. Ann Rheum Dis 1990; 49: 926–928.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993; 36: 75–83.

    Article  CAS  PubMed  Google Scholar 

  26. Steen VD, Medsger Jr TA, Rodnan GP . D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982; 97: 652–659.

    Article  CAS  PubMed  Google Scholar 

  27. Stratton RJ, Wilson H, Black CM . Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001; 40: 84–88.

    Article  CAS  PubMed  Google Scholar 

  28. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299–305.

    Article  CAS  PubMed  Google Scholar 

  29. Freundlich B, Jimenez SA, Steen VD, Medsger Jr TA, Szkolnicki M, Jaffe HS . Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. Arthritis Rheum 1992; 35: 1134–1142.

    Article  CAS  PubMed  Google Scholar 

  30. Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41: 915–922.

    Article  CAS  PubMed  Google Scholar 

  31. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C . Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838–844.

    CAS  PubMed  Google Scholar 

  32. Akesson A, Scheja A, Lundin A, Wollheim FA . Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729–735.

    Article  CAS  PubMed  Google Scholar 

  33. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J . A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325–1329.

    CAS  PubMed  Google Scholar 

  34. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC . Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18: 455–461.

    Article  CAS  PubMed  Google Scholar 

  35. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA . Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947–954.

    Article  CAS  PubMed  Google Scholar 

  36. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG . Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298–304.

    CAS  PubMed  Google Scholar 

  37. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731–736.

    CAS  PubMed  Google Scholar 

  38. Griffiths B, Miles S, Hilary M, Robertson R, Veale D, Emery P . Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371–2378.

    CAS  PubMed  Google Scholar 

  39. Steen VD, Medsger Jr TA . Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613–1619.

    Article  CAS  PubMed  Google Scholar 

  40. Van Laar JM, Farge D, Tyndall A . Autologous stem cell transplantation international scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64: 1515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R K Burt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oyama, Y., Barr, W., Statkute, L. et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 40, 549–555 (2007). https://doi.org/10.1038/sj.bmt.1705782

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705782

Keywords

This article is cited by

Search

Quick links